JAMA Dermatology

<jats:sec><jats:title>Introduction</jats:title><jats:p>A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR).</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>This study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Participants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks.</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>The coprimary efficacy outcomes were (1) proportion of participants with Investigator’s Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; <jats:italic>P</jats:italic> &amp;amp;lt; .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; <jats:italic>P</jats:italic> &amp;amp;lt; .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; <jats:italic>P</jats:italic> = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; <jats:italic>P</jats:italic> &amp;amp;lt; .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, −9.2; 95% CI, −11.5 to −6.9; <jats:italic>P</jats:italic> &amp;amp;lt; .001; MVOR-2: TD, −6.8; 95% CI, −8.9 to −4.8; <jats:italic>P</jats:italic> &amp;amp;lt; .001) and doxycycline (MVOR-1: TD, −4.7; 95% CI, −6.7 to −2.8; <jats:italic>P</jats:italic> &amp;amp;lt; .001; MVOR-2: TD, −3.5; 95% CI, −5.4 to −1.6; <jats:italic>P</jats:italic> &amp;amp;lt; .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>In this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>ClinicalTrials.gov Identifiers: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05296629">NCT05296629</jats:ext-link> and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05343455">NCT05343455</jats:ext-link></jats:p></jats:sec>

Incidence and prevalence of rosacea: a systematic review and meta-analysis.

Br J Dermatol

Rosacea: diagnosis and treatment.

Am Fam Physician

Recommendations for rosacea diagnosis, classification and management: update from the Global Rosacea Consensus 2019 Panel.

Interventions for rosacea.

Cochrane Database Syst Rev

Update on the management of rosacea from the American Acne & Rosacea Society (AARS).

J Clin Aesthet Dermatol

Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents.

Cutis

Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline.

Acta Derm Venereol

Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models.

J Periodontol

Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.

Pharmacol Res

Doxycycline modulates nitric oxide production in murine lung epithelial cells.

J Immunol

Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.

Antimicrob Agents Chemother

Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.

J Rheumatol

Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.

Curr Med Chem

Effects of antibiotics on human polymorphonuclear leukocyte chemotaxis in vitro.

Br J Oral Maxillofac Surg

Clinical significance of brand versus generic formulations: focus on oral minocycline.

Minocycline for acne vulgaris: efficacy and safety.

A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea.

Antibiotics (Basel)

Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial.

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

JAMA

Reliability of Clinician Erythema Assessment grading scale.

J Am Acad Dermatol

Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.

Guidelines of care for the management of acne vulgaris.

Minocycline-induced hyperpigmentation.

J Community Hosp Intern Med Perspect

Comedonal diffusion of minocycline in acne.

Dermatology

Nonantibiotic properties of tetracyclines in rosacea and their clinical implications.

Minocycline: far beyond an antibiotic.

Br J Pharmacol

Minocycline affects human neutrophil respiratory burst and transendothelial migration.

Inflamm Res

Determination of minimum inhibitory concentrations.

J Antimicrob Chemother

Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.

J Drugs Dermatol

Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.

Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.

Clin Infect Dis

Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments.

Adv Ther

Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.

Sci Transl Med

Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility.

A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR).
To determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR.
This study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included.
Participants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks.
The coprimary efficacy outcomes were (1) proportion of participants with Investigator's Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction.
Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P < .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P < .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P < .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, -9.2; 95% CI, -11.5 to -6.9; P < .001; MVOR-2: TD, -6.8; 95% CI, -8.9 to -4.8; P < .001) and doxycycline (MVOR-1: TD, -4.7; 95% CI, -6.7 to -2.8; P < .001; MVOR-2: TD, -3.5; 95% CI, -5.4 to -1.6; P < .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.
In this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR.
ClinicalTrials.gov Identifiers: NCT05296629 and NCT05343455.

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials.

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea

Papers